FK506 As an Adjuvant of Tolerogenic DNA Vaccination for the Prevention of Experimental Autoimmune Encephalomyelitis.

Youmin Kang,Jia Zhao,Yue Liu,Aoshuang Chen,Guoxing Zheng,Yang Yu,Jianjie Mi,Qiang Zou,Bin Wang
DOI: https://doi.org/10.1002/jgm.1387
2009-01-01
The Journal of Gene Medicine
Abstract:Background DNA vaccination is a strategy that has been developed primarily to elicit protective immunity against infection and cancer.Methods DNA vaccine was used, in conjunction with an immunosuppressant, to tolerize harmful autoimmunity.Results Immunization of C57BL/6 mice with MOG(35-55), a myelin oligodendrocyte glycoprotein-derived peptide, and FK506 (Tacrolimus) as a tolerogenic adjuvant stimulated regulatory dendritic cells, induced antigen-specific regulatory T cells (Treg), and protected the animals from subsequent induction of experimental autoimmune encephalomyelitis (EAE). After EAE there were fewer lymphocytes, including fewer T helper 17 cells, induction, and more Treg infiltrating the spinal cord in the immunized mice compared to in control mice. Furthermore, at the peak of the EAE manifestation, CD4 T cells in the immunized mice showed decreased expression of interferon-gamma and interleukin (IL)-17, but not IL-4, in treated mice.Conclusions DNA vaccination, when applied with an immunosuppressant as adjuvant, can induce antigen-specific tolerance and prevent autoimmune disease. Copyright (C) 2009 John Wiley & Sons, Ltd.
What problem does this paper attempt to address?